Answers are grounded in this paper and cite their sources.
Our results show a positive trend for Xpert MTB/RIF market penetration in 21 HBC public sectors. However, GeneXpert machines were under-utilized for TB, and inadequately exploited as a multi disease technology.
No takes yet. Share an insight, caveat, or question.
Cazabon et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: